Cibus, Inc.CBUSEarnings & Financial Report
Cibus, Inc. is a leading agricultural biotechnology firm specializing in precision gene editing technologies to develop improved, sustainable crop traits. Its solutions include herbicide tolerance, disease and pest resistance, and enhanced yield characteristics for major row crops, serving global agricultural markets, seed producers, and farming communities to reduce environmental impact and boost operational efficiency.
CBUS Q4 2025 Key Financial Metrics
Revenue
$1.1M
Gross Profit
N/A
Operating Profit
$-22.6M
Net Profit
$-31.3M
Gross Margin
N/A
Operating Margin
-2135.7%
Net Margin
-2959.9%
YoY Growth
-12.8%
EPS
$-0.39
Financial Flow
Cibus, Inc. Q4 2025 Financial Summary
Cibus, Inc. reported revenue of $1.1M (down 12.8% YoY) for Q4 2025, with a net profit of $-31.3M (down 35.4% YoY) (-2959.9% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $1.1M |
|---|---|
| Net Profit | $-31.3M |
| Gross Margin | N/A |
| Operating Margin | -2135.7% |
| Report Period | Q4 2025 |
Cibus, Inc. Annual Revenue by Year
Cibus, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $3.6M). Click any linked year to see what changed vs the prior annual report.
Cibus, Inc. Quarterly Revenue & Net Profit History
Cibus, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $1.1M | -12.8% | $-31.3M | -2959.9% |
| Q3 2025 | $615.0K | -63.1% | $-23.5M | -3827.8% |
| Q2 2025 | $933.0K | +11.3% | $-25.4M | -2719.4% |
| Q1 2025 | $1.0M | +89.7% | $-46.9M | -4534.4% |
| Q4 2024 | $1.2M | +9.9% | $-23.1M | -1906.1% |
| Q3 2024 | $1.7M | +250.9% | $-180.0M | -10795.9% |
| Q2 2024 | $838.0K | +325.4% | $-24.9M | -2969.3% |
| Q1 2024 | $545.0K | +1197.6% | $-23.4M | -4300.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $545000 | $838000 | $1.7M | $1.2M | $1.0M | $933000 | $615000 | $1.1M |
| YoY Growth | 1197.6% | 325.4% | 250.9% | 9.9% | 89.7% | 11.3% | -63.1% | -12.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $533.0M | $553.4M | $367.9M | $350.1M | $335.0M | $346.2M | $330.2M | $305.0M |
| Liabilities | $213.2M | $246.3M | $247.0M | $252.2M | $261.1M | $271.7M | $278.2M | $283.2M |
| Equity | $278.2M | $270.5M | $108.1M | $92.2M | $70.3M | $72.1M | $50.4M | $21.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-13.5M | $-17.0M | $-13.5M | $-14.0M | $-11.8M | $-13.6M | $-11.7M | $-13.4M |